High grade serous ovarian
tumors often metastasize transperitoneally, a process that begins when small
tumor nodules de-adhere and are released into the fluid of the abdominal cavity where they float freely to reach new sites on the peritoneal wall.
Podocalyxin, a small anti-adhesive
sialomucin, has been shown to contribute to non-adhesive membrane domain formation in some epithelia and is overexpressed in a variety of
cancers. We therefore assessed
podocalyxin expression on a previously characterized tissue microarray and found that 87% (169/194) of high grade serous
epithelial ovarian carcinomas were positive for
podocalyxin. In addition, cell surface localization of
podocalyxin was associated with a significant decrease in disease-free survival in these
tumors. When
podocalyxin was force-expressed in serous ovarian
carcinoma-derived OVCAR-3 cells it was targeted to the cell surface and it decreased the adhesion of these cells to mesothelial monolayers,
fibronectin and immobilized β1
integrin-binding
antibodies. This decrease in adhesion was associated with a modest decrease in cell surface β1
integrin. In monolayer culture,
podocalyxin was targeted to the free, apical domains of OVCAR-3 cells and it appeared to decrease β1
integrin levels on the attached basolateral domains of the same cells. Furthermore, in 3-dimensional basement membrane gel culture, the cells formed small, cohesive nodules and
podocalyxin localized to membrane domains at the cell-basement membrane interface. Therefore,
podocalyxin's ability to facilitate the formation of non-adhesive membrane domains may contribute to the formation of free-floating high grade serous
tumor nodules during the initial steps of transperitoneal
metastasis.